カテゴリ： Allied Market Research, 世界, 医療/バイオ

トキソプラズマ症治療のグローバル市場（2021〜2031）：後天性トキソプラズマ症、先天性トキソプラズマ症

■ 英語タイトル：Toxoplasmosis Treatment Market By Type (Acquired Toxoplasmosis, Congenital Toxoplasmosis), By Route of Administration (Oral, Parenteral), By Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, Online Providers): Global Opportunity Analysis and Industry Forecast, 2021-2031

調査会社Allied Market Research社が発行したリサーチレポート（データ管理コード：ALD23FB174）■ 発行会社/調査会社：Allied Market Research
■ 商品コード：ALD23FB174
■ 発行日：2022年10月
■ 調査対象地域：グローバル
■ 産業分野：医療
■ ページ数：210
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後24時間以内）
■ 販売価格オプション（消費税別）
Online Only（1名閲覧、印刷不可）USD3,570 ⇒換算￥542,640見積依頼/購入/質問フォーム
Single User（1名閲覧）USD5,730 ⇒換算￥870,960見積依頼/購入/質問フォーム
Enterprise User（閲覧人数無制限）USD9,600 ⇒換算￥1,459,200見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※Allied Market Research社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[トキソプラズマ症治療のグローバル市場（2021〜2031）：後天性トキソプラズマ症、先天性トキソプラズマ症]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

Allied Market Research社の本市場調査レポートでは、2021年に683.11百万ドルであった世界のトキソプラズマ症治療市場規模が、2031年までに1,093.88百万ドルに到達し、2022年から2031年にかけてCAGR（年平均成長率）4.8%で成長すると予測しています。本レポートは、トキソプラズマ症治療の世界市場を総合的に調査・分析した資料であり、イントロダクション、エグゼクティブサマリー、市場概要、種類別（後天性トキソプラズマ症、先天性トキソプラズマ症）分析、投与経路別（経口、非経口）分析、流通チャネル別（病院薬局、ドラッグストア・薬局、オンライン供給者）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米・中東・アフリカ）分析、企業状況、企業情報などを掲載しています。また、本レポートは、Alvogen、Dr Reddy's Laboratories Ltd.、Teva Pharmaceutical Industries Limited、Vyera Pharmaceuticals LLC、Mangalam Drugs and Organics Ltd.などの企業情報を含んでいます。
・イントロダクション
・エグゼクティブサマリー
・市場概要
・世界のトキソプラズマ症治療市場規模：種類別
- 後天性トキソプラズマ症の市場規模
- 先天性トキソプラズマ症の市場規模
・世界のトキソプラズマ症治療市場規模：投与経路別
- 経口投与における市場規模
- 非経口投与における市場規模
・世界のトキソプラズマ症治療市場規模：流通チャネル別
- 病院薬局チャネルの市場規模
- ドラッグストア・薬局チャネルの市場規模
- オンライン供給者チャネルの市場規模
・世界のトキソプラズマ症治療市場規模：地域別
- 北米のトキソプラズマ症治療市場規模
- ヨーロッパのトキソプラズマ症治療市場規模
- アジア太平洋のトキソプラズマ症治療市場規模
- 中南米・中東・アフリカのトキソプラズマ症治療市場規模
・企業状況
・企業情報

世界のトキソプラズマ症治療市場は、2021年に6億8,311万ドルと評価され、2022年から2031年までの年平均成長率は4.8%を記録し、2031年には10億9,388万ドルに達すると予測されています。
トキソプラズマ症は、世界で最も一般的な寄生虫の1つであるトキソプラズマ・ゴンディ寄生虫によって発症する病気です。この感染症は通常、加熱不十分な汚染肉を食べたり、感染した猫の糞便に触れたり、妊娠中に母子感染することで発症します。トキソプラズマ症は一部の人にインフルエンザのような症状を引き起こすことがありますが、感染者の大半は何の症状も示しません。
世界のトキソプラズマ症治療市場の成長は、主に食中毒の有病率の増加によってもたらされます。また、トキソプラズマ症の治療と診断における技術的進歩が市場の成長を促進します。さらに、米国などの先進国におけるトキソプラズマ症治療に関する意識の高まりが、市場の成長をさらに促進します。

さらに、世界中でHIVの有病率が増加しているため、HIV感染者の免疫反応が低下してトキソプラズマ・ゴンディ感染のリスクが高まっており、これがトキソプラズマ症治療に対する需要の増加につながり、市場の成長を促進しています。例えば、世界保健機関（WHO）によると、2021年末までに、全世界で約3,840万人がHIVに感染して生活しており、そのため、世界人口の間でトキソプラズマ症感染の有病率が増加し、市場成長を促進すると予想されています。
さらに、アジア太平洋地域における医療、産業開発、政府および民間組織による投資の急増、およびトキソプラズマ症疾患に関する意識の高まりは、予測期間中に市場にプラスの影響を与えると予想されます。さらに、主要な市場参入企業によるトキソプラズマ症治療の上市は、市場成長を後押しする要因となっています。例えば、Dr. Reddy’s Laboratories Ltd.は、米国食品医薬品局（USFDA）からトキソプラズマ症治療として承認されたピリメタミン錠USP、25mgの発売を発表しました。
しかし、トキソプラズマ症治療の副作用や高額な治療費が市場成長の妨げとなっています。逆に、トキソプラズマ症治療のための製品承認の増加は、市場プレーヤーに有利な機会を提供すると予想されます。

トキソプラズマ症治療市場は、種類、投与経路、流通チャネル、地域に基づいてセグメント化されます。種類別では、市場は後天性トキソプラズマ症と先天性トキソプラズマ症に分類されます。投与経路別では、市場は経口剤と非経口剤に分別されます。流通チャネル別では、市場は病院薬局、ドラッグストア・小売薬局、オンラインプロバイダーに分類されます。地域別では、北米（米国、カナダ、メキシコ）、欧州（ドイツ、フランス、英国、イタリア、スペイン、その他の欧州地域）、アジア太平洋地域（日本、中国、オーストラリア、インド、韓国、その他のアジア太平洋地域）、LAMEA（ブラジル、南アフリカ、サウジアラビア、その他のLAMEA地域）に市場を分けて分析しています。

世界のトキソプラズマ症治療市場で事業を展開する主な主要企業は、Alvogen、Dr. Reddy’s Laboratories Ltd.、Kaiser Permanente、Mangalam Drugs and Organics Ltd.、Manus Aktteva Biopharma LLP、Oakrum Pharma、Omicron pharmaceuticals、Teva Pharmaceutical Industries Ltd.、Vyera Pharmaceuticals LLC、Zorish Healthcare Private Limitedです。

〈ステークホルダーにとっての主なメリット〉
・本レポートは、2021年から2031年までのトキソプラズマ症治療市場分析の市場セグメント、現在の動向、予測、ダイナミクスを定量的に分析し、トキソプラズマ症治療市場の有力な市場機会を特定します。
・主要な促進要因、阻害要因、機会に関する情報とともに市場調査を提供します。
・ポーターのファイブフォース分析により、バイヤーとサプライヤーの潜在力を明らかにし、ステークホルダーが利益志向のビジネス決定を行い、サプライヤーとバイヤーのネットワークを強化できるようにします。
・トキソプラズマ症治療市場のセグメンテーションを詳細に分析することで、市場機会を見極めることができます。
・トキソプラズマ症治療の市場細分化に関する詳細な分析により、市場機会を見極めることができます。
・市場プレイヤーのポジショニングはベンチマーキングを容易にし、市場プレイヤーの現在のポジションを明確に理解することができます。
・地域別および世界のトキソプラズマ症治療市場動向、主要企業、市場セグメント、応用分野、市場成長戦略の分析を含みます。

〈主要市場セグメント〉
種類別
後天性トキソプラズマ症
先天性トキソプラズマ症

投与経路別
経口剤
非経口剤

流通経路別
病院薬局
ドラッグストア・小売薬局
オンラインプロバイダー

地域別
・北米
米国
カナダ
メキシコ
・ヨーロッパ
ドイツ
フランス
イギリス
イタリア
スペイン
その他のヨーロッパ
・アジア太平洋
日本
中国
インド
オーストラリア
韓国
その他のアジア太平洋地域
・LAMEA
ブラジル
サウジアラビア
南アラビア
その他のLAMEA地域

〈主要市場プレイヤー〉
Alvogen
Dr Reddy’s Laboratories Ltd.
Teva Pharmaceutical Industries Limited
Vyera Pharmaceuticals LLC
Mangalam Drugs and Organics Ltd.
Oakrum Pharma
Kaiser Permanente
Zorish Healthcare Private Limited
omicron pharmaceuticals
Manus Aktteva Biopharma LLP

世界の市場調査レポート販売サイト（H&Iグローバルリサーチ株式会社運営）
*** レポート目次（コンテンツ）***

CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter’s five forces analysis
3.4.Top player positioning
3.5.Market dynamics
3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
CHAPTER 4: TOXOPLASMOSIS TREATMENT MARKET, BY TYPE
4.1 Overview
4.1.1 Market size and forecast
4.2 Acquired Toxoplasmosis
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market share analysis by country
4.3 Congenital Toxoplasmosis
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market share analysis by country
CHAPTER 5: TOXOPLASMOSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
5.1 Overview
5.1.1 Market size and forecast
5.2 Oral
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market share analysis by country
5.3 Parenteral
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market share analysis by country
CHAPTER 6: TOXOPLASMOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL
6.1 Overview
6.1.1 Market size and forecast
6.2 Hospital Pharmacies
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market share analysis by country
6.3 Drug Stores and Retail Pharmacies
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market share analysis by country
6.4 Online Providers
6.4.1 Key market trends, growth factors and opportunities
6.4.2 Market size and forecast, by region
6.4.3 Market share analysis by country
CHAPTER 7: TOXOPLASMOSIS TREATMENT MARKET, BY REGION
7.1 Overview
7.1.1 Market size and forecast
7.2 North America
7.2.1 Key trends and opportunities
7.2.2 North America Market size and forecast, by Type
7.2.3 North America Market size and forecast, by Route of Administration
7.2.4 North America Market size and forecast, by Distribution Channel
7.2.5 North America Market size and forecast, by country
7.2.5.1 U.S.
7.2.5.1.1 Key market trends, growth factors and opportunities
7.2.5.1.2 Market size and forecast, by Type
7.2.5.1.3 Market size and forecast, by Route of Administration
7.2.5.1.4 Market size and forecast, by Distribution Channel
7.2.5.2 Canada
7.2.5.2.1 Key market trends, growth factors and opportunities
7.2.5.2.2 Market size and forecast, by Type
7.2.5.2.3 Market size and forecast, by Route of Administration
7.2.5.2.4 Market size and forecast, by Distribution Channel
7.2.5.3 Mexico
7.2.5.3.1 Key market trends, growth factors and opportunities
7.2.5.3.2 Market size and forecast, by Type
7.2.5.3.3 Market size and forecast, by Route of Administration
7.2.5.3.4 Market size and forecast, by Distribution Channel
7.3 Europe
7.3.1 Key trends and opportunities
7.3.2 Europe Market size and forecast, by Type
7.3.3 Europe Market size and forecast, by Route of Administration
7.3.4 Europe Market size and forecast, by Distribution Channel
7.3.5 Europe Market size and forecast, by country
7.3.5.1 Germany
7.3.5.1.1 Key market trends, growth factors and opportunities
7.3.5.1.2 Market size and forecast, by Type
7.3.5.1.3 Market size and forecast, by Route of Administration
7.3.5.1.4 Market size and forecast, by Distribution Channel
7.3.5.2 France
7.3.5.2.1 Key market trends, growth factors and opportunities
7.3.5.2.2 Market size and forecast, by Type
7.3.5.2.3 Market size and forecast, by Route of Administration
7.3.5.2.4 Market size and forecast, by Distribution Channel
7.3.5.3 UK
7.3.5.3.1 Key market trends, growth factors and opportunities
7.3.5.3.2 Market size and forecast, by Type
7.3.5.3.3 Market size and forecast, by Route of Administration
7.3.5.3.4 Market size and forecast, by Distribution Channel
7.3.5.4 Italy
7.3.5.4.1 Key market trends, growth factors and opportunities
7.3.5.4.2 Market size and forecast, by Type
7.3.5.4.3 Market size and forecast, by Route of Administration
7.3.5.4.4 Market size and forecast, by Distribution Channel
7.3.5.5 Spain
7.3.5.5.1 Key market trends, growth factors and opportunities
7.3.5.5.2 Market size and forecast, by Type
7.3.5.5.3 Market size and forecast, by Route of Administration
7.3.5.5.4 Market size and forecast, by Distribution Channel
7.3.5.6 Rest of Europe
7.3.5.6.1 Key market trends, growth factors and opportunities
7.3.5.6.2 Market size and forecast, by Type
7.3.5.6.3 Market size and forecast, by Route of Administration
7.3.5.6.4 Market size and forecast, by Distribution Channel
7.4 Asia-Pacific
7.4.1 Key trends and opportunities
7.4.2 Asia-Pacific Market size and forecast, by Type
7.4.3 Asia-Pacific Market size and forecast, by Route of Administration
7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel
7.4.5 Asia-Pacific Market size and forecast, by country
7.4.5.1 Japan
7.4.5.1.1 Key market trends, growth factors and opportunities
7.4.5.1.2 Market size and forecast, by Type
7.4.5.1.3 Market size and forecast, by Route of Administration
7.4.5.1.4 Market size and forecast, by Distribution Channel
7.4.5.2 China
7.4.5.2.1 Key market trends, growth factors and opportunities
7.4.5.2.2 Market size and forecast, by Type
7.4.5.2.3 Market size and forecast, by Route of Administration
7.4.5.2.4 Market size and forecast, by Distribution Channel
7.4.5.3 India
7.4.5.3.1 Key market trends, growth factors and opportunities
7.4.5.3.2 Market size and forecast, by Type
7.4.5.3.3 Market size and forecast, by Route of Administration
7.4.5.3.4 Market size and forecast, by Distribution Channel
7.4.5.4 Australia
7.4.5.4.1 Key market trends, growth factors and opportunities
7.4.5.4.2 Market size and forecast, by Type
7.4.5.4.3 Market size and forecast, by Route of Administration
7.4.5.4.4 Market size and forecast, by Distribution Channel
7.4.5.5 South Korea
7.4.5.5.1 Key market trends, growth factors and opportunities
7.4.5.5.2 Market size and forecast, by Type
7.4.5.5.3 Market size and forecast, by Route of Administration
7.4.5.5.4 Market size and forecast, by Distribution Channel
7.4.5.6 Rest of Asia-Pacific
7.4.5.6.1 Key market trends, growth factors and opportunities
7.4.5.6.2 Market size and forecast, by Type
7.4.5.6.3 Market size and forecast, by Route of Administration
7.4.5.6.4 Market size and forecast, by Distribution Channel
7.5 LAMEA
7.5.1 Key trends and opportunities
7.5.2 LAMEA Market size and forecast, by Type
7.5.3 LAMEA Market size and forecast, by Route of Administration
7.5.4 LAMEA Market size and forecast, by Distribution Channel
7.5.5 LAMEA Market size and forecast, by country
7.5.5.1 Brazil
7.5.5.1.1 Key market trends, growth factors and opportunities
7.5.5.1.2 Market size and forecast, by Type
7.5.5.1.3 Market size and forecast, by Route of Administration
7.5.5.1.4 Market size and forecast, by Distribution Channel
7.5.5.2 Saudi Arabia
7.5.5.2.1 Key market trends, growth factors and opportunities
7.5.5.2.2 Market size and forecast, by Type
7.5.5.2.3 Market size and forecast, by Route of Administration
7.5.5.2.4 Market size and forecast, by Distribution Channel
7.5.5.3 South Arabia
7.5.5.3.1 Key market trends, growth factors and opportunities
7.5.5.3.2 Market size and forecast, by Type
7.5.5.3.3 Market size and forecast, by Route of Administration
7.5.5.3.4 Market size and forecast, by Distribution Channel
7.5.5.4 Rest of LAMEA
7.5.5.4.1 Key market trends, growth factors and opportunities
7.5.5.4.2 Market size and forecast, by Type
7.5.5.4.3 Market size and forecast, by Route of Administration
7.5.5.4.4 Market size and forecast, by Distribution Channel
CHAPTER 8: COMPANY LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments
CHAPTER 9: COMPANY PROFILES
9.1 Alvogen
9.1.1 Company overview
9.1.2 Company snapshot
9.1.3 Operating business segments
9.1.4 Product portfolio
9.1.5 Business performance
9.1.6 Key strategic moves and developments
9.2 Dr Reddy’s Laboratories Ltd.
9.2.1 Company overview
9.2.2 Company snapshot
9.2.3 Operating business segments
9.2.4 Product portfolio
9.2.5 Business performance
9.2.6 Key strategic moves and developments
9.3 Teva Pharmaceutical Industries Limited
9.3.1 Company overview
9.3.2 Company snapshot
9.3.3 Operating business segments
9.3.4 Product portfolio
9.3.5 Business performance
9.3.6 Key strategic moves and developments
9.4 Vyera Pharmaceuticals LLC
9.4.1 Company overview
9.4.2 Company snapshot
9.4.3 Operating business segments
9.4.4 Product portfolio
9.4.5 Business performance
9.4.6 Key strategic moves and developments
9.5 Mangalam Drugs and Organics Ltd.
9.5.1 Company overview
9.5.2 Company snapshot
9.5.3 Operating business segments
9.5.4 Product portfolio
9.5.5 Business performance
9.5.6 Key strategic moves and developments
9.6 Oakrum Pharma
9.6.1 Company overview
9.6.2 Company snapshot
9.6.3 Operating business segments
9.6.4 Product portfolio
9.6.5 Business performance
9.6.6 Key strategic moves and developments
9.7 Kaiser Permanente
9.7.1 Company overview
9.7.2 Company snapshot
9.7.3 Operating business segments
9.7.4 Product portfolio
9.7.5 Business performance
9.7.6 Key strategic moves and developments
9.8 Zorish Healthcare Private Limited
9.8.1 Company overview
9.8.2 Company snapshot
9.8.3 Operating business segments
9.8.4 Product portfolio
9.8.5 Business performance
9.8.6 Key strategic moves and developments
9.9 omicron pharmaceuticals
9.9.1 Company overview
9.9.2 Company snapshot
9.9.3 Operating business segments
9.9.4 Product portfolio
9.9.5 Business performance
9.9.6 Key strategic moves and developments
9.10 Manus Aktteva Biopharma LLP
9.10.1 Company overview
9.10.2 Company snapshot
9.10.3 Operating business segments
9.10.4 Product portfolio
9.10.5 Business performance
9.10.6 Key strategic moves and developments

LIST OF TABLES
TABLE 1. GLOBAL TOXOPLASMOSIS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 2. TOXOPLASMOSIS TREATMENT MARKET FOR ACQUIRED TOXOPLASMOSIS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 3. TOXOPLASMOSIS TREATMENT MARKET FOR ACQUIRED TOXOPLASMOSIS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 4. TOXOPLASMOSIS TREATMENT MARKET FOR CONGENITAL TOXOPLASMOSIS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 5. TOXOPLASMOSIS TREATMENT MARKET FOR CONGENITAL TOXOPLASMOSIS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 6. GLOBAL TOXOPLASMOSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
TABLE 7. TOXOPLASMOSIS TREATMENT MARKET FOR ORAL, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 8. TOXOPLASMOSIS TREATMENT MARKET FOR ORAL, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 9. TOXOPLASMOSIS TREATMENT MARKET FOR PARENTERAL, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 10. TOXOPLASMOSIS TREATMENT MARKET FOR PARENTERAL, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 11. GLOBAL TOXOPLASMOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 12. TOXOPLASMOSIS TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 13. TOXOPLASMOSIS TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 14. TOXOPLASMOSIS TREATMENT MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 15. TOXOPLASMOSIS TREATMENT MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 16. TOXOPLASMOSIS TREATMENT MARKET FOR ONLINE PROVIDERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 17. TOXOPLASMOSIS TREATMENT MARKET FOR ONLINE PROVIDERS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 18. TOXOPLASMOSIS TREATMENT MARKET, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 19. NORTH AMERICA TOXOPLASMOSIS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 20. NORTH AMERICA TOXOPLASMOSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
TABLE 21. NORTH AMERICA TOXOPLASMOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 22. NORTH AMERICA TOXOPLASMOSIS TREATMENT MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 23. U.S. TOXOPLASMOSIS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 24. U.S. TOXOPLASMOSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
TABLE 25. U.S. TOXOPLASMOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 26. CANADA TOXOPLASMOSIS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 27. CANADA TOXOPLASMOSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
TABLE 28. CANADA TOXOPLASMOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 29. MEXICO TOXOPLASMOSIS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 30. MEXICO TOXOPLASMOSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
TABLE 31. MEXICO TOXOPLASMOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 32. EUROPE TOXOPLASMOSIS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 33. EUROPE TOXOPLASMOSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
TABLE 34. EUROPE TOXOPLASMOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 35. EUROPE TOXOPLASMOSIS TREATMENT MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 36. GERMANY TOXOPLASMOSIS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 37. GERMANY TOXOPLASMOSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
TABLE 38. GERMANY TOXOPLASMOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 39. FRANCE TOXOPLASMOSIS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 40. FRANCE TOXOPLASMOSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
TABLE 41. FRANCE TOXOPLASMOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 42. UK TOXOPLASMOSIS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 43. UK TOXOPLASMOSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
TABLE 44. UK TOXOPLASMOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 45. ITALY TOXOPLASMOSIS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 46. ITALY TOXOPLASMOSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
TABLE 47. ITALY TOXOPLASMOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 48. SPAIN TOXOPLASMOSIS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 49. SPAIN TOXOPLASMOSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
TABLE 50. SPAIN TOXOPLASMOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 51. REST OF EUROPE TOXOPLASMOSIS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 52. REST OF EUROPE TOXOPLASMOSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
TABLE 53. REST OF EUROPE TOXOPLASMOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 54. ASIA-PACIFIC TOXOPLASMOSIS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 55. ASIA-PACIFIC TOXOPLASMOSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
TABLE 56. ASIA-PACIFIC TOXOPLASMOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 57. ASIA-PACIFIC TOXOPLASMOSIS TREATMENT MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 58. JAPAN TOXOPLASMOSIS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 59. JAPAN TOXOPLASMOSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
TABLE 60. JAPAN TOXOPLASMOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 61. CHINA TOXOPLASMOSIS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 62. CHINA TOXOPLASMOSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
TABLE 63. CHINA TOXOPLASMOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 64. INDIA TOXOPLASMOSIS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 65. INDIA TOXOPLASMOSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
TABLE 66. INDIA TOXOPLASMOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 67. AUSTRALIA TOXOPLASMOSIS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 68. AUSTRALIA TOXOPLASMOSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
TABLE 69. AUSTRALIA TOXOPLASMOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 70. SOUTH KOREA TOXOPLASMOSIS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 71. SOUTH KOREA TOXOPLASMOSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
TABLE 72. SOUTH KOREA TOXOPLASMOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 73. REST OF ASIA-PACIFIC TOXOPLASMOSIS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 74. REST OF ASIA-PACIFIC TOXOPLASMOSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
TABLE 75. REST OF ASIA-PACIFIC TOXOPLASMOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 76. LAMEA TOXOPLASMOSIS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 77. LAMEA TOXOPLASMOSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
TABLE 78. LAMEA TOXOPLASMOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 79. LAMEA TOXOPLASMOSIS TREATMENT MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 80. BRAZIL TOXOPLASMOSIS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 81. BRAZIL TOXOPLASMOSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
TABLE 82. BRAZIL TOXOPLASMOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 83. SAUDI ARABIA TOXOPLASMOSIS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 84. SAUDI ARABIA TOXOPLASMOSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
TABLE 85. SAUDI ARABIA TOXOPLASMOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 86. SOUTH ARABIA TOXOPLASMOSIS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 87. SOUTH ARABIA TOXOPLASMOSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
TABLE 88. SOUTH ARABIA TOXOPLASMOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 89. REST OF LAMEA TOXOPLASMOSIS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 90. REST OF LAMEA TOXOPLASMOSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
TABLE 91. REST OF LAMEA TOXOPLASMOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 92.ALVOGEN: COMPANY SNAPSHOT
TABLE 93.ALVOGEN: OPERATING SEGMENTS
TABLE 94.ALVOGEN: PRODUCT PORTFOLIO
TABLE 95.ALVOGEN: NET SALES
TABLE 96.ALVOGEN: KEY STRATERGIES
TABLE 97.DR REDDY'S LABORATORIES LTD.: COMPANY SNAPSHOT
TABLE 98.DR REDDY'S LABORATORIES LTD.: OPERATING SEGMENTS
TABLE 99.DR REDDY'S LABORATORIES LTD.: PRODUCT PORTFOLIO
TABLE 100.DR REDDY'S LABORATORIES LTD.: NET SALES
TABLE 101.DR REDDY'S LABORATORIES LTD.: KEY STRATERGIES
TABLE 102.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT
TABLE 103.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: OPERATING SEGMENTS
TABLE 104.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO
TABLE 105.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: NET SALES
TABLE 106.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: KEY STRATERGIES
TABLE 107.VYERA PHARMACEUTICALS LLC: COMPANY SNAPSHOT
TABLE 108.VYERA PHARMACEUTICALS LLC: OPERATING SEGMENTS
TABLE 109.VYERA PHARMACEUTICALS LLC: PRODUCT PORTFOLIO
TABLE 110.VYERA PHARMACEUTICALS LLC: NET SALES
TABLE 111.VYERA PHARMACEUTICALS LLC: KEY STRATERGIES
TABLE 112.MANGALAM DRUGS AND ORGANICS LTD.: COMPANY SNAPSHOT
TABLE 113.MANGALAM DRUGS AND ORGANICS LTD.: OPERATING SEGMENTS
TABLE 114.MANGALAM DRUGS AND ORGANICS LTD.: PRODUCT PORTFOLIO
TABLE 115.MANGALAM DRUGS AND ORGANICS LTD.: NET SALES
TABLE 116.MANGALAM DRUGS AND ORGANICS LTD.: KEY STRATERGIES
TABLE 117.OAKRUM PHARMA: COMPANY SNAPSHOT
TABLE 118.OAKRUM PHARMA: OPERATING SEGMENTS
TABLE 119.OAKRUM PHARMA: PRODUCT PORTFOLIO
TABLE 120.OAKRUM PHARMA: NET SALES
TABLE 121.OAKRUM PHARMA: KEY STRATERGIES
TABLE 122.KAISER PERMANENTE: COMPANY SNAPSHOT
TABLE 123.KAISER PERMANENTE: OPERATING SEGMENTS
TABLE 124.KAISER PERMANENTE: PRODUCT PORTFOLIO
TABLE 125.KAISER PERMANENTE: NET SALES
TABLE 126.KAISER PERMANENTE: KEY STRATERGIES
TABLE 127.ZORISH HEALTHCARE PRIVATE LIMITED: COMPANY SNAPSHOT
TABLE 128.ZORISH HEALTHCARE PRIVATE LIMITED: OPERATING SEGMENTS
TABLE 129.ZORISH HEALTHCARE PRIVATE LIMITED: PRODUCT PORTFOLIO
TABLE 130.ZORISH HEALTHCARE PRIVATE LIMITED: NET SALES
TABLE 131.ZORISH HEALTHCARE PRIVATE LIMITED: KEY STRATERGIES
TABLE 132.OMICRON PHARMACEUTICALS: COMPANY SNAPSHOT
TABLE 133.OMICRON PHARMACEUTICALS: OPERATING SEGMENTS
TABLE 134.OMICRON PHARMACEUTICALS: PRODUCT PORTFOLIO
TABLE 135.OMICRON PHARMACEUTICALS: NET SALES
TABLE 136.OMICRON PHARMACEUTICALS: KEY STRATERGIES
TABLE 137.MANUS AKTTEVA BIOPHARMA LLP: COMPANY SNAPSHOT
TABLE 138.MANUS AKTTEVA BIOPHARMA LLP: OPERATING SEGMENTS
TABLE 139.MANUS AKTTEVA BIOPHARMA LLP: PRODUCT PORTFOLIO
TABLE 140.MANUS AKTTEVA BIOPHARMA LLP: NET SALES
TABLE 141.MANUS AKTTEVA BIOPHARMA LLP: KEY STRATERGIES

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • オランザピンのグローバル市場（2021〜2031）：統合失調症、双極性障害、その他
  • ペプチド治療薬のグローバル市場（2021〜2031）：代謝、腫瘍、胃腸、神経、心血管、その他
  • 乾癬治療のグローバル市場（2021〜2031）：TNF-α阻害剤、インターロイキン阻害剤、その他
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(ALD23FB174 )"トキソプラズマ症治療のグローバル市場（2021〜2031）：後天性トキソプラズマ症、先天性トキソプラズマ症" (英文：Toxoplasmosis Treatment Market By Type (Acquired Toxoplasmosis, Congenital Toxoplasmosis), By Route of Administration (Oral, Parenteral), By Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, Online Providers): Global Opportunity Analysis and Industry Forecast, 2021-2031)はAllied Market Research社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。